A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor. - Wikidata - wikimedia - TriplyDB

A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor.

A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor.

http://www.wikidata.org/entity/Q34342259

about

Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathways New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma 2-Hydoxyglutarate: D/Riving Pathology in gLiomaS Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches Regulation of substrate utilization by the mitochondrial pyruvate carrier Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone Selenite inhibits glutamine metabolism and induces apoptosis by regulating GLS1 protein degradation via APC/C-CDH1 pathway in colorectal cancer cells.Inhibition of glutamine metabolism counteracts pancreatic cancer stem cell features and sensitizes cells to radiotherapy.Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.Glutaminolysis as a target for cancer therapy.Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype.Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport.Gene alterations and epigenetic changes in intrahepatic cholangiocarcinoma.Perspectives on investigational drugs and immunotherapies for glioblastoma.Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs.Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays [18F](2S,4R)4-Fluoroglutamine PET Detects Glutamine Pool Size Changes in Triple-Negative Breast Cancer in Response to Glutaminase Inhibition.Wild-type and mutated IDH1/2 enzymes and therapy responses.Glutamine Metabolism in Gliomas.

P2860

Q26861539-10A028FD-56E5-4ECD-BB9D-58EF76BF2525 Q26863394-2DD5094A-0A5D-43D8-A295-E8758E282C52 Q28087807-8EB23BC9-F242-4AAF-9284-AAD2848EA57F Q33759313-9228C3E3-82E0-4BFF-B261-C588B653DA2F Q33835913-62B894B5-2421-422E-B59D-E4025789F729 Q34710980-83462A73-05D4-45BF-A201-B6069A8817EA Q36146939-CCDC9AD9-CE22-48C5-A036-A546BCF889F1 Q37745850-20DB12FD-AB13-495A-8DFD-C72E47A04598 Q38260557-8CCADA54-9FAD-4B37-B396-3FE7C748989D Q38428692-116B9649-46CB-4DC2-A80B-DAB69B5F8201 Q38526029-D1A96399-162F-470B-9F59-B599E6EF54CB Q38537883-9E35026F-11BE-4448-945B-9C00885AFD0B Q38642387-700B2F9C-A975-48FF-A6CD-F5ECDEB0DC04 Q38874166-2C477EBB-93F2-4CC8-A211-3DD6BFA5F4C2 Q38933788-5A9C7473-CFD2-40C4-9805-33619A3DB306 Q39022105-6C43BA47-F4DC-43C4-ADDA-DD00F628F448 Q41064782-C00EA96D-BADE-4AA3-B8BE-15FE811622B6 Q42116442-6917F919-A171-4477-A6B0-E8B5DC1064E4 Q42371843-1BE55BC1-EAEE-4A0B-8472-2197114E5950 Q47235205-74D78B08-8C29-4DDA-A4EA-6A4550F6AA79 Q47713415-5F07C069-65B9-4A3F-900C-61A44787F533 Q48417468-181A9415-D866-48F3-B436-0F0A4CDF932C

P2860

A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor.

http://www.wikidata.org/entity/Q34342259

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A high-throughput fluorimetric ...... st as a glutaminase inhibitor.

@ast

A high-throughput fluorimetric ...... st as a glutaminase inhibitor.

@en

A high-throughput fluorimetric ...... st as a glutaminase inhibitor.

@nl

type

label

A high-throughput fluorimetric ...... st as a glutaminase inhibitor.

@ast

A high-throughput fluorimetric ...... st as a glutaminase inhibitor.

@en

A high-throughput fluorimetric ...... st as a glutaminase inhibitor.

@nl

prefLabel

A high-throughput fluorimetric ...... st as a glutaminase inhibitor.

@ast

A high-throughput fluorimetric ...... st as a glutaminase inhibitor.

@en

A high-throughput fluorimetric ...... st as a glutaminase inhibitor.

@nl

P1433

Q34342259-9A0C6936-F8CA-4FF6-BD59-92CBBCFB2318

P1476

Q34342259-ECF016E4-B26D-49D3-83FD-657D4CA11542

P2093

Q34342259-21D41D09-7406-4714-A6DB-D48A35B61217

Q34342259-231C5A85-4543-4E31-812D-1130F2A4B072

Q34342259-7E073B5E-E71E-4124-B157-0E62D1FCE05C

Q34342259-9B52E9A4-958C-4986-9AA4-3B3F73F3C95D

Q34342259-D479EAA6-C02C-4A3C-8E29-003594B42A21

Q34342259-DC952650-FDDA-4109-A6D3-6580BC0F4833

P2860

Q34342259-03FE1A6B-A575-45E7-B049-A74E89D8F6CC

Q34342259-15CAD34F-1B6F-41C1-A764-4F4017342F3E

Q34342259-1A2F0ACA-E557-4EAE-9CE6-4242CFAC459B

Q34342259-2CD8F486-3E44-4ADB-BA47-2AAD13EE8C1A

Q34342259-38BF6BCB-FD1D-479A-83E3-81F8F0556221

Q34342259-3E34D4F9-E3E6-4A19-82AE-94513B547E7A

Q34342259-3E638B7D-7F0F-436E-A8D5-463DFD5F8646

Q34342259-5B2691D4-771B-48E0-8E16-A676F732C179

Q34342259-647C3F76-4E1F-4F4D-B472-8322F57C714B

Q34342259-687725B2-1038-4251-9713-E4C1A3F7BB8F

P304

Q34342259-B3960CC2-9F38-4B5F-BB06-8C50088BEEC8

P31

Q34342259-221746A2-F2CF-422C-A39F-54790B041CE3

P356

Q34342259-F7586AE2-DD89-45A9-A7E2-F1E7DB761E64

P433

Q34342259-647FF339-0E51-4376-95EF-A1FFCF114807

P478

Q34342259-618906DD-73F7-4E73-A24D-6041319D5912

P577

Q34342259-2C5A57F9-B3D9-4444-8A7C-68DF03110B75

P698

Q34342259-43F79812-19BF-4AEB-946B-F255BEF7A523

P932

Q34342259-A0A6D2FF-6A03-4813-AE6A-7BA9A07A315B

P356

2159-8290.CD-13-0572

P1433

Cancer Discovery

P1476

A high-throughput fluorimetric ...... st as a glutaminase inhibitor.

@en

P2093

Adnan Elhammali

http://www.w3.org/2001/XMLSchema#string

David Piwnica-Worms

http://www.w3.org/2001/XMLSchema#string

Jan Crowley

http://www.w3.org/2001/XMLSchema#string

Jayne Marasa

http://www.w3.org/2001/XMLSchema#string

Joseph E Ippolito

http://www.w3.org/2001/XMLSchema#string

Lynne Collins

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

Recurring mutations found by sequencing an acute myeloid leukemia genome

An integrated genomic analysis of human glioblastoma multiforme

IDH1 and IDH2 mutations in gliomas

A novel alpha-ketoglutarate reductase activity of the serA-encoded 3-phosphoglycerate dehydrogenase of Escherichia coli K-12 and its possible implications for human 2-hydroxyglutaric aciduria

Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

IDH mutation impairs histone demethylation and results in a block to cell differentiation

P304

828-839

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-13-0572

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24740997

http://www.w3.org/2001/XMLSchema#string

P932

4197823

http://www.w3.org/2001/XMLSchema#string